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Abstract 
The synthesis and characterization of four organometallic gold(I) complexes containing 
different water soluble phosphanes (TPPTS, PTA and DAPTA) and chromophoric units 
(4-pyridylethynyl and propargyloxycoumarin) is here reported. The analysis of their 
absorption and emission spectra led us to attribute their luminescent behaviour to the 
chromophoric organic ligands. Moreover, the presence of the gold(I) metal atom has 
been observed to be the responsible of an efficient intersystem crossing process 
responsible for the observed phosphorescence emission. Broad emission bands are 
observed in most cases due to the formation of organized aggregates in solution in 
agreement with microscopic characterization. 
Biological activity of the complexes showed very low effects against tumor cell growth 
but an inhibitory potency against thioredoxin reductase (TrxR). The missing / low 
cytotoxic effects could be related to a low bioavailability as determined by atomic 
absorption spectroscopy. 
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1. Introduction 
Gold based compounds form a new family of cytotoxic agents of great interest as 
metallodrugs and the lead compound auranofin is currently undergoing clinical trials in 
the US as an anticancer agent. Nevertheless, the precise mechanisms of antitumor 
activity of gold compounds have not been completely understood yet.
1,2
 The 
mechanistic studies show that in general DNA is not the main target
3
 and the 
selenoenzyme thioredoxin reductase, a putative and now partially validated main target 
for many cytotoxic gold compounds,
4-10
 although other mechanisms besides TrxR 
inhibition might contribute to the biological profile (e.g., interactions with G-
quadruplexes).
11-14
 In particular, gold-phosphine compounds were investigated after the 
antiarthritic drug auranofin (thiolate–Au-PEt3complex) and were found to present 
biological activity against different cancer cells. A series of auranofin analogues 
containing thiolate ligands were prepared, as well as bis(phosphine)Au(I), phosphane–
gold-halides and phosphine-gold-alkynyl complexes.
15
 Solubility is always an issue for 
drug administration, which is a limit that many potential anticancer metal complexes 
have to overcome. Flanking the phosphine with an appropriate co-ligand yields active 
complexes and both the steric and electronic properties appear to be important in the 
design of effective gold complexes.
16
 The resulting solubility could be also tuned. It was 
also observed that the presence of a direct metal-carbon bond in Au(I) and Au(III) 
complexes appears to be rather beneficial for their stability and speciation in aqueous 
solutions. For this, various organometallic gold complexes were synthesized in which 
the presence of a direct carbon-gold bond greatly stabilizes the gold oxidation state and 
guarantees more controlled chemical speciation in biological systems.
17
 Among 
organometallic gold(I) complexes, recent initial reports on the bioactivity of alkynyl 
gold complexes indicate that this type of complexes offers opportunities for the 
3 
 
development of new chemotherapeutics against cancer and infectious diseases. Despite 
their potential, only very few studies on the biological potential of alkynyl gold 
complexes have been reported so far.
18-23
 Moreover, gold alkynyl complexes are well-
known to display interesting luminescent properties that have been an interesting tool 
within the biological point of view among others.
24
 Of note, gold(I) alkynyl derivatives 
containing the water-soluble 1,3,5-triaza-7-phosphaadamantane (PTA) and 3,7-diacetyl-
1,3,7-triaza-5-phosphabicyclo[3.3.1]-nonane (DAPTA) phosphane ligands are cytotoxic 
in cancer cells and their cellular uptake was confirmed by fluorescence microscopy 
using the luminescent properties of these organometallics.
18
 These phosphanes are 
particularly appealing due to their solubility in water that increases the global solubility 
of the complexes in this medium. 
Recently, we reported on the luminescence and biological properties of a series of Au(I) 
alkynyl complexes containing the water soluble phosphanes PTA and DAPTA and a 
strong inhibition of the TrxR enzyme was observed.
23
 Their observed gel formation in 
water could be also considered to investigate as a possible effect to affect the drug 
transfer through the cell membrane.
25-27
 Following the previous studies, we have 
designed new water soluble complexes with some differences on their chemical 
structure (Chart 1) in order to analyze how these chemical modifications could affect 
both on their luminescent and biological properties. 
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2. Experimental Section 
2.1. General procedures  
All manipulations were performed under prepurified N2 using standard Schlenk 
techniques. All solvents were distilled from appropriated drying agents. Commercial 
reagent triphenylphosphine-3,3’,3”-trisulfonic acid trisodium salt (TPPTS, Aldrich, 
95%), 1,3,5-triaza-7-phosphaadamantane (PTA, Aldrich 97%) and 3,7-diacetyl-1,3,7-
triaza-5-phosphabicyclo[3.3.1]nonane (DAPTA, Aldrich 97%) were used as received. 
Literature methods were used to prepare 4-ethynylpyridine,
28
 Na3[AuCl(TPPTS)],
29
 
[AuCl(PTA)],
30
 [AuCl(DAPTA)],
30
 7-(prop-2-in-1-yloxy)-1-benzopyran-2-one
23
  and 
[Au(C≡Cpy)]n.
31
 PBS: phosphate buffered saline pH 7.4; cell culture medium: 
minimum essential medium eagle; 30 % Danieau medium: 58 mM NaCl, 0.7 mM KCl, 
0.4 mM MgSO4, 0.6 mM Ca(NO3)2 and 5 mM HEPES (pH 7.2). 
 
2.2. Physical measurements 
Infrared spectra were recorded on a FT-IR 520 Nicolet Spectrophotometer. 
1
H-NMR 
(δ(TMS) = 0.0 ppm), 31P{1H}-NMR (δ(85% H3PO4) = 0.0 ppm) spectra were obtained 
on a Varian Mercury 400, Bruker 400 and Bruker DMX 500. ESI spectra were recorded 
on a Fisons VG Quatro spectrometer. Absorption spectra were carried out on a Varian 
Cary 100 Bio UV- spectrophotometer and emission spectra on a Horiba-Jobin-Ybon 
SPEX Nanolog spectrofluorimeter. Emission quantum yields were measured at 298 K 
relative to quinine sulphate (F = 0.54, H2SO4 1N) for compound 1 and 7-methoxy-4-
methylcoumarin as a reference (F = 0.124, methanol) for compounds 2-4, in water. 
Optical microscopy was recorded on an Olympus BX51. Scanning electron microscopy 
was carried out a 5kV using a Neon40 Crossbeam Station (Zeiss) equipped with a field 
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emission gun. A MALVERN Zetasizer Nano S operating at 173° scattering angle and 
25 °C was used to perform the dynamic light scattering (DLS) measurements. 
 
2.3. HR-CS AAS measurements 
A contrAA© 700 high-resolution continuum source atomic absorption spectrometer 
(Analytik Jena AG) was used for the gold quantification in cell lysates. Gold was 
measured at a wavelength of 242.7950 nm. Samples were injected at a volume of 20 µl 
into coated standard graphite tubes AnalytikJena AG). Calibration was done in a matrix 
matched manner and pure samples of the gold complexes were used to prepare the 
standard solutions. The mean integrated absorbances (AUC = area under the curve) of 
triple injections were used throughout the study.  
 
2.4. TrxR inhibitory effects 
To determine the inhibition of TrxR an established microplate reader based assay was 
performed with minor modifications.
32 
For this purpose commercially available 
thioredoxin reductase from rat liver (Sigma-Aldrich) was used and diluted with distilled 
water. The compounds were freshly dissolved as stock solutions in DMF. To each 25 μl 
aliquots of the enzyme solution each 25 μl of potassium phosphate buffer pH 7.0 
containing the compounds in graded concentrations or vehicle (DMF) without 
compounds (control probe) were added and the resulting solutions (final concentration 
of DMF: max. 0.5% V/V) were incubated with moderate shaking for 75 minutes at 
37°C in a 96 well plate. To each well 225 μl of reaction mixture (1000 μl reaction 
mixture consisted of 500 μl potassium phosphate buffer pH 7.0, 80 μl 100 mM EDTA 
solution pH 7.5, 20 μl BSA solution 0.2%, 100 μl of 20 mM NADPH solution and 300 
μl of distilled water) were added and the reaction was started by addition of 25 μl of an 
20 mM ethanolic dithio-bis-2-nitrobenzoic acid (DTNB) solution. After proper mixing, 
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the formation of 5-thio-2-nitrobenzoic acid (5-TNB) was monitored with a microplate 
reader (Perkin Elmer Victor X4) at 405 nm in 35 s intervals for 350 s. For each tested 
compound the non interference with the assay components was confirmed by a negative 
control experiment using an enzyme free solution. The IC50 values were calculated as 
the concentration of compound decreasing the enzymatic activity of the untreated 
control by 50% and are given as the means and error of 2 - 3 independent experiments. 
 
2.5. Cell Culture and antiproliferative effects  
MDA-MB-231 breast adenocarcinoma and HT-29 colon carcinoma were maintained in 
DMEM high glucose (PAA) supplemented with 50 mg/L gentamycin and 10% (V/V) 
fetal calf serum (FCS) at 37°C under 5% CO2 atmosphere and passaged every seven 
days. Antiproliferative effects were determined essentially as described in a recent 
publication.
11,20,22
 A volume of 100 µl of a 38.000 cells/ml (HT-29) or 40.000 cells/ml 
(MDA-MB-231) suspension were seeded into 96-well plates and incubated for 48 hours 
at 37 °C and 5% CO2. After the incubation period the cells in one plate were fixed by 
addition of 100 µl of a 10% glutaraldehyde solution and the plate was stored at 4 °C (t0 
plate). Stock solutions of the compounds were freshly prepared in DMF and diluted 
with cell culture medium to the final concentrations (0.1% v/v DMF). In the remaining 
plates the medium was replaced by different concentrations of the compound in cell 
culture medium (6 wells for each concentration). Twelve wells of each plate were 
treated with a solution of 0.1% DMF in cell culture medium (untreated control). Then 
the plates were incubated for 72 h (HT-29) or 96 h (MDA-MB-231) at 5% CO2 and 37 
°C. The medium was removed and the cells were treated with 100 µl of a 10% 
glutaraldehyde solution. Afterwards the cells of all plates were washed with 180 µL 
PBS and stained with 100 µl of a 0.02% crystal violet solution for 30 minutes. The 
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crystal violet solution was removed and the plates were washed with water and dried. A 
volume of 180 µl of ethanol 70% was added to each well and after 3-4 h of gentle 
shaking the absorbance was measured at 595 nm in a microplate reader (Victor X4, 
PerkinElmer). The mean absorbance value of the t0 plate was subtracted from the 
absorbance values of all other absorbance values. The IC50-values were calculated as the 
concentrations reducing the cellular proliferation in comparison with the untreated 
control by 50% and are given as the means and errors of 2 - 3 independent experiments. 
 
2.6. Cellular uptake 
For cellular uptake studies cells were grown until at least 70 % confluency in 25 cm
2
 
cell culture flasks. Stock solutions of the compounds in DMF were freshly prepared and 
diluted with cell culture medium to the desired concentration of 10 and 50 µM. The cell 
culture medium of the cell culture flasks was replaced with 3 ml of the cell culture 
medium containing the gold compound and the flasks were incubated at 37 °C / 5 % 
CO2 for 6 h. Subsequent to the incubation period the culture medium was removed and 
cells were washed with 3 ml PBS. Cells were resuspended in 3 mL PBS by using a cell 
scratcher and cell pellets were isolated by centrifugation (RT, 3323 g, 5 min). Cellular 
lysates were prepared by resuspending an isolated cell pellet in 300 µl demineralized 
water followed by ultrasonication. An aliquot was removed for the purpose of protein 
quantification by the method of Bradford.
 
The metal content of the samples was 
determined by high-resolution continuum source atomic absorption spectrometry (HR-
CS AAS, see above). To avoid matrix effects matrix-matched calibration was used for 
gold quantification in the samples. To 20 µl of all injected probes and standards each 2 
µl Triton X100 (1 %) were added. Results were calculated from the data of 2-3 
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independent experiments and are expressed as the cellular molar gold concentration 
(µM), which was determined as described in a previous report.
33,34
 
 
2.7. Synthesis of Na3[Au(C≡C-py)(TPPTS)] (1). Solid KOH (5 mg, 0.75 mmol) was 
added to a solution of NC5H4-C≡CH (7 mg, 0.75 mmol) in MeOH (15 ml). After 30 min 
of stirring at room temperature, solid [AuCl(TPPTS)] (60 mg, 0.75  mmol) was added 
and the solution was stirred for 2 hours at room temperature. The resulting white 
solution was concentrated, and diethyl ether (15 ml) was added to precipitate a white 
solid. The pure compound was obtained by recrystallizing twice the solid dissolved in a 
H2O:MeOH mixture, using diethyl ether as the precipitating agent. Yield: 91%. 
1
H-
NMR (400 MHz, D2O): 8.40 (d, J = 12.0 Hz, 2H, Hα-pyr), 7.27 (d, J = 12.0 Hz, 2H, Hβ-
pyr), 7.97-7.95 (m, 6H, H3, H6), 7.72-7.63 (m, 6H, H2, H4). 
31
P{
1
H}-NMR (400 MHz, 
D2O): -40.9.  IR (KBr, cm
-1
): 3455 (C-H), 2119 (C≡C), 1588 (C=N). ESI-MS (-) m/z: 
265.98 [M – 3H]3-, 399.47 [M – 2H]2-, 410.47 [M – 3H + Na]2-, 418.45 [M – 3H + K]2- 
([M]
-
, calc.: 868.50). Anal. Calc. C, 34.69, H, 1.86, N, 1.61, S, 11.09 %; Found C, 
34.72, H, 1.88, N, 1.63, S, 11.11 %. 
 
2.8. Synthesis of Na3[Au(C≡C-C10H7O3)(TPPTS)] (2).  Solid KOH (5 mg, 0.75 
mmol) was added to a solution of 7-(prop-2-in-1-yloxy)-1-benzopyran-2-one (15 mg, 
0.75 mmol) in MeOH (10 ml). After 30 min of stirring at room temperature, solid 
[AuCl(TPPTS)] (60 mg, 0.75 mmol) was added and the solution was stirred for 2 hours 
at room temperature. The resulting yellow solution was concentrated (5 ml) and n-
hexane (10 ml) was added to precipitate a yellow solid. The pure compound was 
obtained by recrystallizing twice the solid dissolved in a H2O:MeOH mixture, using 
diethyl ether as the precipitating agent. Yield: 83%. 
1
H-NMR (400 MHz, D2O): 8.14 (d, 
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J = 8.0 Hz, 1H, H3), 8.00-7.81 (m, 6H, H6’, H5’), 7.73-6.85 (m, 9H, H2’, H4’ + H5+ H8+ 
H6), 6.30 (d, J = 8.0 Hz, 1H, H4), 4.44 (s, 2H, H9). 
31
P{
1
H}-NMR (400 MHz, D2O): -
33.49.  IR (KBr, cm
-1): 2120 (C≡C), 1730 (C=O). ESI-MS (-) m/z: 940.92 [M – Na]-, 
458.97 [(M – 2Na)/2]2-, 447.97 [(M – 3Na)/2]2-, 298.31 [(M – 3Na)/3]3- ([M]+, calc.: 
965.60). Anal. Calc. C, 37.36, H, 1.99 %, S, 9.97 %; Found C, 37.38, H, 2.01 %, S, 9.95 
%. 
 
2.9. Synthesis of 6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one (PC67) 
Solid 6, 7-dihydroxy-1-benzopyran-2-one (300 mg, 1.65 mmol) and K2CO3 (570 mg, 
4.13 mmol) were mixed in deoxygenated acetone (30 ml). After 5 min of stirring, 
propargyl bromide (459 μL, 4.13 mmol) was added dropwise and the mixture was 
refluxed during 5 days. The solution of the reaction was concentrated to dryness, 
extracted with ethyl acetate–H2O and recrystallized with ethyl acetate–hexane to give 
364 mg of a pale yellow solid in 87% yield. 
1
H-NMR (400 MHz, 298 K, CDCl3): 7.63 
(d, 1H, J = 9.5 Hz, H3), 7.10 (s, 1H, H8), 7.06 (s, 1H, H5), 6.32 (d, 1H, J = 9.5 Hz, H4), 
4.83 (d, 2H, J = 2.4 Hz, H10), 4.79 (d, 2H, J = 2.4 Hz, H9), 2.59 (t, 1H, J = 2.4 Hz, 
H12), 2.55 (t, 1H, J = 2.4 Hz, H11). IR (KBr, cm
-1): 3266, 3239 (≡C-H), 2216 (C≡C), 
1705 (C=O). ESI-MS (+) m/z: 255.07 ([M + H]
+
, calc. 255.06), 277.05 ([M + Na]
+
, calc. 
277.05), 531.10 ([2M + Na]
+
, calc. 531.12). Anal. Calc. C, 70.86, H, 3.96 %; Found C, 
70.89, H, 3.98 %. 
 
2.10. Synthesis of [Au{6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one}(PTA)2] (3) 
Solid KOH (27 mg, 0.48 mmol) was added to a mixture of 6,7-bis(prop-2-in-1-yloxy)-
1-benzopyran-2-one (60 mg, 0.24 mmol) in methanol (10 ml). After 5 min of stirring a 
dichloromethane solution (15 ml) of [AuCl(PTA)] (139 mg, 0.34 mmol) was added and 
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the mixture was maintained at room temperature protected from light with aluminium 
foil. After 2 hours of stirring, the solution was concentrated to ca. 15 ml and hexane (10 
ml) was added to precipitate a pale yellow solid. The pure compound was obtained by 
recrystallizing twice the solid dissolved in a CH2Cl2:MeOH mixture, using diethyl ether 
as the precipitating agent. Yield: 46 % (75 mg). 
1
H-NMR (400 MHz, 298 K, CDCl3): 
7.64 (d, 1H, J = 9.5 Hz, H3), 7.14 (s, 1H, H8), 7.11 (s, 1H, H5), 6.24 (d, 1H, J = 9.5 
Hz, H4), 4.88 (s, 2H, H10), 4.85 (s, 2H, H9), 4.55-4.43 (AB q (br), 12H, J = 16.0 Hz, 
N-CH2-N), 4.26 (s (br), 12H, N-CH2-P). 
31
P{
1
H}-NMR (162 MHz, 298 K, CDCl3): -
51.4 (br). IR (KBr, cm
-1): 2127 (C≡C), 1707 (C=O). ESI-MS (+) m/z: 961.13 ([M + H]+, 
calc. 961.14), 983.12 ([M + Na]
+
, calc. 983.12), 999.09 ([M + K]
+
, calc. 999.09). Anal. 
Calc. C, 33.76, H, 3.36, N, 8.75 %; Found C, 33.77, H, 3.39, N, 8.74%. 
 
2.11. Synthesis of [Au{6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one}(DAPTA)2] 
(4) 
Solid KOH (21 mg, 0.37 mmol) was added to a mixture of 6,7-bis(prop-2-in-1-yloxy)-
1-benzopyran-2-one (47 mg, 0.19 mmol) in methanol (10 mL). After 5 min of stirring a 
dichloromethane solution (15 mL) of [AuCl(DAPTA)] (169 mg, 0.36 mmol) was added 
and the mixture was maintained at room temperature protected from light with 
aluminium foil and stirred during 24 h. Then, the solution was concentrated to ca. 15 
mL and hexane (30 mL) was added to precipitate a pale yellow solid. The pure 
compound was obtained by recrystallizing twice the solid dissolved in a CH2Cl2:MeOH 
mixture, using diethyl ether as the precipitating agent. Yield = 80% (160 mg). 
1
H-NMR 
(400 MHz, 298 K, CDCl3):7.62 (d, 1H, J = 9.4 Hz, H3), 6.98 (s (br), 2H, H8, H5), 
6.27 (d, 1H, J = 9.4 Hz, H4), 5.80-5.61 (m (br), 4H, H9, H10), 5.03-4.77 (m (br), 8H, 
DAPTA), 4.67-4.57 (m (br), 2H, DAPTA) 4.46 (s (br), 2H, DAPTA), 4.26-4.00 (m (br), 
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6H, DAPTA), 3.84 (s (br), 2H, DAPTA), 2.11 (s (br), 6H, N-CO-CH3 (DAPTA)), 2.08 
(s (br), 6H, N-CO-CH3 (DAPTA)). 
31
P{
1
H}-NMR (162 MHz, 298 K, CDCl3): -24.7 
(br). IR (KBr, cm
-1): 2125 (C≡C), 1718, 1637 (C=O).ESI-MS (+) m/z: 1127.16 ([M + 
Na]
+
, calc. 1127.16). Anal. Calc. C, 35.88, H, 3.65, N, 7.61; Found C, 35.91, H, 3.68, N, 
7.58 %. 
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3. Results and Discussion 
3.1. Synthesis and Characterization 
3.1.1. Synthesis of mononuclear gold(I) derivatives. 
In order to analyse the influence of the negatively charged phosphane TPPTS in the 
spectroscopic and biological properties of Au(I) 4-pyridylethynyl complexes, the 
complex Na3[Au(C≡C-py)(TPPTS)] was synthesized. The reaction was carried out by 
deprotonation of the terminal alkynyl proton of the 4-pyridylethynyl ligand with a KOH 
methanol solution and addition of a stoichiometric amount of [AuCl(TPPTS)] complex 
(previously synthesized) in the same medium (Scheme 1). 
 
 
 
 
 
 
Scheme 1. Synthesis of Na3[Au(C≡C-py)(TPPTS)] (1). 
 
 
The synthesis of this complex was firstly attempted by the reaction of [Au(C≡C-py)]n 
with the TPPTS phosphine, following the procedure used for the analogous neutral 
complexes [Au(C≡C-py)(PR3)] (PR3 = PTA,
25
 DAPTA
26
) previously reported by us but 
the reaction was not accomplished.  
The complex Na3[Au(C≡C-C10H7O3)(TPPTS)], containing a propargyloxy group 
instead of pyridylethynyl, was successfully obtained by the same synthethic procedure 
(Scheme 2) in high yields (80-90%). 
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Scheme 2. Synthesis of Na3[Au(C≡C-C10H7O3)(TPPTS)] (2) 
 
Characterization of the complexes by 
1
H and 
31
P-NMR and IR spectroscopy and ESI(-) 
mass spectrometry indicates the correct formation of the complexes. The presence of the 
molecular peak recorded in both cases by ESI-MS(-) indicates the presence of the 
complexes. IR and 
1
H-NMR spectra show the disappearance of the terminal alkynyl 
proton being a crucial signal of their successful preparation. The presence of the 
negatively charged phosphane made these complexes highly soluble in polar media 
(D2O and DMSO) and almost insoluble in CDCl3, as a difference with the 
corresponding derivatives with PTA and DAPTA phosphanes.
25,26
 
The detailed analysis of the NMR data made us to realise that some kind of aggregates 
must be present in 1. In this case, pyridyl protons could only be observed by 
1
H-NMR 
recorded in D2O at diluted concentrations and these signals were broad and trended to 
disappear when increasing concentration (Figure 1). 
31
P-NMR spectrum was also in 
agreement with the formation of aggregates and displayed two broad peaks with similar 
chemical environment that become broader when increasing concentration (Figure S3). 
The formation of these large supramolecular structures was also verified by optical and 
electronic microscopy (see below). 
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Figure 1. 
1
H-NMR spectrum of 1 at 1·10
-3
M (up) and 1·10
-4
M (bottom) concentrations 
in D2O.  
 
3.1.2. Synthesis of dinuclear gold(I) derivatives. 
New dinuclear complexes were designed and synthesized in order to analyse how the 
presence of two metal atoms could affect on their photophysical and aggregation 
properties and / or could present a cooperative effect on their biological activity. The 
synthesis of the 6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one (PC67) was undertaken 
following the procedure used for the related compounds containing only one prop-2-in-
1-yloxy groups (Scheme S1).
23
  6,7-hydroxycoumarin was made react with propargyl 
bromide in acetone at 50ºC for 5 days and in the presence of K2CO3 to give the 
corresponding bis-propynyloxycoumarin in pure form after recrystallization in ethyl 
acetate / hexane (1) in very high yield (ca. 90%). The reaction of PC67 with 
[AuCl(PR3)] (PR3 = PTA (3), DAPTA (4)) in the required stoichiometric conditions led 
us to obtain the dinuclear complexes 3 and 4 by similar procedure detailed above for 
mononuclear derivatives (Schemes 3 and S2). Similar reaction was attempted by using 
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Na3[AuCl(TPPTS)] derivative but it was not possible to obtain the desired dinuclear 
complex in pure form. 
 
 
 
 
 
Scheme 3. Synthesis of [Au{6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one}(PTA)2] 
(3). 
 
Characterization of the complexes by 
1
H and 
31
P-NMR and IR spectroscopy and ESI(+) 
mass spectrometry indicates the formation of the complexes. As reported for 1 and 2, IR 
and 
1
H-NMR in CDCl3 show the disappearance of the terminal alkynyl proton being the 
key point that points out the successful preparation of the complexes. The 
corresponding protons of the phosphane follow the typical patterns of PTA and DAPTA 
together with the expected protons of the coumarin unit (Figures S6 and S7). It could be 
observed that the signals present some broadening due to the slightly unequivalence of 
both phosphanes and to the possible aggregation effect. This effect is strongly favoured 
in water, where the compounds display lower solubility, as confirmed by microscopy 
and photophysical studies (see below). 
31
P-NMR shows a downfield shift of about -50 
ppm  for PTA and -20 ppm for DAPTA derivatives respectively, upon coordination of 
the phosphane to the gold(I) metal atom, as observed for other similar 
compounds.
18,23,25,26,34
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3.1.3. Dynamic Light Scattering experiments 
The presence of aggregates in solution was also evidenced by Dynamic Light Scattering 
(DLS) experiments in water, in agreement with NMR data. Different concentrations 
were used in each case depending on the solubility of the complexes in this solvent and 
are in the range 1·10
-3
M to 1·10
-5
M. The results are summarized in Table 1 and Figures 
S8-S11. As expected, the size of the structures increases with concentration. 
 
Table 1. Size of the aggregates of 1-4 in water. 
a
 The lower solubility of this complex in 
water precludes the measurement at higher concentration. 
b
 Two different populations 
were recorded for this complex. 
Compound Concentration (M) Size (nm) 
1 1·10
-4
, 5·10
-4
 472, 580 
2 1·10
-4
, 1·10
-3
 73, 96 
3 2.5·10
-5 a
 275, 903 
b
 
4 5·10
-5
, 1·10
-4
 152, 175 
 
As a general trend, it can be observed that complexes 1 and 2, containing the TPPTS 
phosphine, are more soluble and the experiments could be undertaken at higher 
concentrations. The lower interaction between molecules observed by complex 2 is 
shown by the lower aggregates’ size recorded by DLS. Coumarin derivatives containing 
PTA and DAPTA phosphines (3 and 4) aggregate at lower concentrations and, as 
expected, the lower solubility of the PTA complex in water gives rise to the formation 
of larger aggregated structures.  
This behaviour seems to be maintained in dried samples as observed by optical and 
electronic microscopy images (see below). 
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 3.1.4. Characterization by Optical and Electronic Microscopy.Optical and Scanning 
Electronic Microscopy have been used to detect the presence of some aggregates in 
other analogous Au(I) alkynyl derivatives in water and their corresponding sizes and 
shapes.
25,26,35
 For this reason, dried samples of 1-4 were deposited adequately to be 
observed under optical microscopy and SEM (Figure 2). Unfortunately, the small 
aggregates of 2 preclude their detection by these techniques. 
 
 
Figure 2. Optical microscopy images of dried samples of 1 (A), 3 (B) and 4 (C) and 
SEM images of 1 (D), 3 (E) and 4 (F) previously dissolved in water. 
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Optical and electronic microscopies show the formation of concentric fibrilar structures 
for 1 that grow from smaller spherical particles. These fibrilar supramolecular 
assemblies were also observed for the neutral complexes [Au(C≡C-py)(PTA)]25 and 
[Au(C≡C-py)(DAPTA)],26 pointing out the key role of the pyridyl moiety on the 
resulting aggregation motif. On the other hand, complexes 3 and 4 present a different 
pattern. PTA derivative, 3, gives rise to the formation of rod-like structures of ca. 3 mm 
length while the higher steric hindrance of the DAPTA phosphine in 4 seem to have a 
direct role on the formation of smaller and spherical aggregates of ca. 100 nm. 
Moreover, the presence of two Au-phosphane groups has also a direct influence on the 
resulting assemblies, since long fibers were very recently observed for the mononuclear 
[Au{7-(prop-2-ine-1-yloxy)-1-benzopyran-2-one}(DAPTA)] hydrogelator.
27
 
 
3.1.5. Absorption and Emission properties. 
The photophysical characterization of Au(I) alkynyl complexes is a denoted research 
field in gold(I) organometallic chemistry since this property can be used for a wide 
range of different applications.
24
 For this reason, absorption and emission spectra of all 
complexes were recorded at ca. 10
-5
 M concentration and the results are summarized in 
Table 2. As we were also interested on their potential biological evaluation, these 
measurements were carried out in water. The absorption, emission and excitation 
spectra displayed for all complexes resemble those of the relative mononuclear 
complexes containing the PTA and DAPTA phosphanes.
23
 Hence, their photophysical 
properties are expected to be dependent on the nature of the chromophoric organic part 
of the molecules. 
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Table 2. Absorption and emission data of complexes 1-4. Emission spectra were 
recorded upon excitation at the lowest energy absorption band. 
a
The fluorescence 
standard reference was quinine sulfate (QY = 0.55, H2SO4 0.5 M, 298 K).
1
 
b
The 
fluorescence standard reference was 7-methoxy-4-methylcoumarin (QY = 0.124, 
MeOH, 298 K). 
 
Compound  
Absorption 
λmax (nm) 
(10
-3
 ε (M-1 cm-1)) 
 
Emission 
(solution,  
λmax (nm)) 
 
QY 
 
        
 1
a
   265 (22.7), 276 (23.5)  410, 430, 442 0.008  
 2
b
  316 (13.5)   392, 450 0.26  
 3
b
  298 (8.8), 336 (8.5)  440 0.03  
 4
b
  300 (10.1), 333 (10.5)   432 0.04  
 
The pyridylethynyl moiety of 1 displays a vibronically structured absorption band 
assigned to intraligand (IL) π-π* (C≡Cpy) transition.25,26 This transition displays some 
broadening which is agreement with that observed in the analogous neutral complexes, 
where the Au-C≡Cpy moiety is directly involved in the aggregation process. The 
vibronically structured emission band in 1 (with progressional spacings at ca. 2000 cm
-
1
) suggests an intraligand 
3[π-π*(alkynyl)] emission origin (Figure 3).  
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Figure 3. Absorption (solid line); excitation (dotted line, em = 470 nm) and emission 
(dashed line, exc = 275 nm) of a 2·10
-5
M solution of 1 in water. 
 
The coumarin absorption bands of 2-4 are centred at 320-350 nm and present the 
same profiles. This indicates that the recorded electronic spectra correspond to * 
transitions of the coumarin group (Figure S12). It is well known that the photophysical 
properties of the coumarin derivatives can be tuned with small changes in the 
substituents and their position.
36
 Thus, complex 2 (with only one substituent at the 7 
position) display a similar shape with a blue shifted band in comparison with that 
recorded for 3 and 4 (with two substituents at 6 and 7 position). Similar extinction 
coefficients were recorded in comparison with the mononuclear derivatives previously 
reported,
23
 in agreement with the presence of only one coumarin chromophoric unit. 
Emission spectra recorded upon excitation of all the samples at the lowest energy 
band display two different profiles (Figure 4). Two broad emission bands centered at 
392 and 450 nm were recorded for the mononuclear complex, 2, while a single broad 
emission band centered at ca. 440 nm was observed for the dinuclear complexes 3 and 
4. 
22 
 
 Excitation spectra collected at the emission maxima reproduce absorption of the 
coumarin units (Figure 4), which is indicative of the origin of these emission bands. The 
large Stokes’ shift of all the lowest energy emission bands and the comparison with 
other coumarin derivatives,
23
 make us to assign the emission as phosphorescence of the 
coumarin which could be favoured by the presence of the gold metal atoms (heavy atom 
effect) that induces population of the triplet emissive state. Moreover, the highest 
energy emission band recorded for 2 (392 nm) corresponds to fluorescence of the 
coumarin unit. Thus, this is a nice example about how the heavy atom effect makes a 
direct influence on the intersystem crossing and induces phosphorescence, being more 
favoured when the molecule contains two gold metal atoms.  
On the other hand, the emission spectra of 3 and 4 are broader than the recorded for 
2, being in agreement with the presence of more aggregated structures in the sample that 
are the responsible of their photophysical properties. 
 
 
 
 
 
 
 
 
 
Figure 4. Normalized excitation (collected at emission maxima) and emission spectra 
(excitation at the absorption maxima) of 2·10
-5
 M solutions of 2-4 in water. 
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Total luminescence quantum yields were measured related to quinine sulphate or 7-
methoxy-4-methylcoumarin and demonstrate that coumarin derivatives present stronger 
luminescent than complex 1, containing pyridyl unit. Especially relevant is the high 
value measured for 2 that makes it suitable candidate to be used as fluorescent marker in 
cells (see below). 
 
3.2. Biological studies 
The biological evaluation was focused on determining the effects against tumor cell 
growth in HT-29 colon carcinoma and MDA-MB-231 breast cancer (Table 3), the 
inhibitory potency against the enzyme thioredoxin reductase and the cellular uptake into 
MDA-MB-231 cancer cells.  
 
Table 3. IC50 values for cytotoxicity in HT-29 and MDA-MB-231 cells; n.d., not 
determined. Mean values ± errors of 2 - 3 independent experiments. 
Complex MDA-MB-231 HT-29 
1 > 100 µM > 100 µM 
2 > 50 µM > 100 µM 
3 51.78 ±0.69 µM > 75 µM 
4 > 100 µM > 100 µM 
   
With the exception of a moderate cytotoxic effect of 3 against MDA-MB-231 cells, the 
complexes did not trigger significant cell growth inhibitory effects. This may be related 
to the above described aggregation effects that had hampered the biological assays 
concerning solubility in aqueous environment at higher dosages.  
[Au(PC7
)(TPPS)] 
[Au(py)(
TPPS)] 
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In order to clarify the bioavailability of the complexes under cell culture conditions we 
determined the cellular gold uptake by atomic absorption spectroscopy (Figure 5).
34
 The 
cellular uptake behaviour of a compound is strongly influenced by its lipophilicity. A 
rather lipophilic neutral complex can easily penetrate the cell membranes by passive 
diffusion. Complexes 1 and 2 are charged species but also lipophilic. The highest 
intracellular gold levels could be observed for 1 indicating that the pyridylethynyl unit 
is more beneficial for cell membrane penetration than the propargyloxycoumarin moiety 
which is present in the complexes 2-4. However, in comparison with previous results 
the levels obtained with 1 are comparably low despite the rather high exposure 
concentrations of 10 and 50 µM.
20,33,37
 Cellular gold levels for 2-4 were barely 
detectable. Taken together, this indicates that low bioavailability is the main reason for 
the missing (low) cytotoxicity of the complexes under study. 
 
Figure 5. Cellular gold accumulation in MDA-MB-231 cells after 6 h exposure to 10 
and 50 µM of the complexes 1 – 4.  Mean values ± errors of 2 – 3 independent 
experiments. Cellular uptake of 2 was not detectable. 
 
 
Related to our previous studies, which had shown strong TrxR inhibition for several 
gold alkynyl complexes, we studied the effects of 1-4 on TrxR activity. For this purpose 
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we screened all complexes in a pilot experiment and determined an exact IC50 values for 
the most active complex 2. The obtained value of 0.055±0.017 µM for TrxR inhibition 
by 2 agrees well with the previously reported strong inhibitory potency of gold(I) 
alkynyl complexes.
20,33 
 
The relevant role of the presence of two metal atoms of 3 and 4 should be highlighted in 
comparison with previous studies carried out with mononuclear PTA and DAPTA 
phosphines containing the same chromophoric unit.
23
 The very low biological activity 
of the complexes herein reported demonstrates the direct effect of the presence of two 
Au-phosphine units in the chemical structure of 3 and 4 in the studied processes with a 
significant decrease on the IC50 values and TrxR inhibition. 
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4. Conclusions 
The synthesis of new organometallic gold(I) derivatives containing an alkynyl unit with 
a pyridyl or propargyloxycoumarin chromophore and water soluble phosphanes at 
second coordinative position of the metal atom has given rise to the formation of water 
soluble complexes. Characterization by NMR and microscopy show the formation of 
well organized aggregates in water. 
The analysis of their photophysical properties shows that the species display emission 
from the chromophoric unit in all cases. Moreover, the presence of the gold heavy atom 
induces the population of the triplet state and hence, phosphorescence emission. This 
intersystem crossing is more favoured for the dinuclear complexes (two heavy atoms in 
the molecule). 
The biological screening showed low / missing cytotoxic effects. This is most likely 
related to the low bioavailability as evidenced by measuring the cellular gold levels 
using atomic absorption spectroscopy. On the other hand, comparison with previous 
data obtained for analogous mononuclear complexes containing PTA or DAPTA 
phosphines
23
 indicated that structure activity relationships regarding the potential 
cytotoxic activity could be related to the energy for Au-P bond dissociation. The higher 
measured IC50 values could be directly related to the more difficult process to cleavage 
the Au-P bond and the involvement of this step in the biological activity. In the case of 
complexes 1 and 2, the presence of the anionic phosphine TPPTS increases the electron 
density of the Au-P. In the case of 3 and 4, the presence of two phosphine-Au-alkynyl 
arms coordinated to the coumarin chromophore (instead of one in Au{7-(prop-2-in-1-
yloxy)-1-benzopyran-2-one}-(phosph)] (phosph = PTA, DAPTA)
23
) may be the reason 
for the increasing of the IC50 value. This fact could be an important factor to consider in 
the design of new phosphine-gold(I)-alkynyl complexes.  
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For complex 2 strong inhibition of the target enzyme TrxR was confirmed. However, 
due to its very low (missing) cellular uptake the strong TrxR inhibition by 2 did not 
translate into cytotoxic effects in the proliferation assays. Future studies should 
therefore focus on improving the bioavailability of the complexes while maintaining 
their strong TrxR inhibition. 
The luminescent properties of our complexes together with their lack of cytotoxicity 
make them important candidates to be used as fluorescent markers, mainly complex 2. 
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5. Supporting Information 
Synthesis of 6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one (PC67) (Scheme S1); 
Synthesis of [Au{6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one}(DAPTA)2] (4) 
(Scheme S2); HR-ESI(-) mass spectrum of Na3[Au(C≡C-C5H4N)(TPPTS)] (1) (Figure 
S1); HR-ESI(-) mass spectrum for the compound Na3[Au(C≡C-C10H7O3)(TPPTS)] (2) 
(Figure S2); 
1
H-NMR spectrum of 1 at 1·10
-3
M (up) and 1·10
-4
M (bottom) 
concentrations in D2O (Figure S3); HR-ESI(-) mass spectrum for the compound 
[Au{6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one}(PTA)2] (3) (Figure S4); HR-
ESI(-) mass spectrum for the compound [Au{6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-
2-one}(DAPTA)2] (4) (Figure S5); 
1
H-NMR spectrum of [Au{6,7-bis(prop-2-in-1-
yloxy)-1-benzopyran-2-one}(PTA)2] (3) in CDCl3 (Figure S6); 
1
H-NMR spectrum of 
[Au{6,7-bis(prop-2-in-1-yloxy)-1-benzopyran-2-one}(DAPTA)2] (4) in CDCl3 (Figure 
S7); DLS measurements of 1 in water at 1·10
-4
M and 5·10
-4
M concentrations (Figure 
S8); DLS measurements of 2 in water at 1·10
-4
M and 1·10
-3
M concentrations  (Figure 
S9); DLS measurements of 3 in water at 2.5·10
-5
M concentration  (Figure S10); DLS 
measurements of 4 in water at 5·10
-5
M and 1·10
-4
M concentrations (Figure S11); 
Normalized absorption spectra of 2-4 in water (Figure S12). 
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